Primitive neuroectodermal tumor (PNET) is a malignant tumor that develops from cells of the nervous system. PNET is most often found in children, but can also occur in adults. This tumor, which belongs to the group of neuroectodermal neoplasms, is characterized by an aggressive course and a high tendency to metastasize. Depending on the location of the tumor, the clinical picture can vary significantly, including headaches, neurological disorders, behavioral changes, and other symptoms associated with the effect on the central and peripheral nervous system. Despite advances in diagnostics and treatment, PNET remains one of the complex problems of pediatric oncology due to its malignancy and specificity with respect to the age group of patients.
History of the disease and interesting historical facts
The history of the study of neuroectodermal tumors dates back to the early twentieth century, when physicians began to classify different types of brain tumors. In 1926, the term “primitive neuroectodermal tumor” was introduced to describe tumors originating from immature neuronal cells. In the following decades, pathology developed, allowing for more precise identification of these tumors. In the 1970s, it was recognized that PNETs were a distinct tumor type, distinct from other neuroectodermal neoplasms such as medulloblastoma and astrocytomas. Important milestones in the study of PNETs were the investigation of the molecular mechanisms of its pathogenesis, which made it possible to identify genetic changes that characterize this tumor. This demonstrates the importance of PNETs in pediatric oncology, as well as the need for further research to improve diagnosis and treatment tactics.
Epidemiology
The epidemiology of primitive neuroectodermal tumor shows that this disease is a relatively rare form of cancer. According to the American Cancer Society, the incidence of PNET is about 2.5 cases per 1 million people per year. The disease is most often registered in children under 10 years of age, with a peak incidence in the first and second years of life. Compared with other malignant tumors, PNET ranks approximately 2% among all childhood tumors. There is also a slight predominance among boys: for every 100 girls, there are approximately 130 boys with this tumor. These data emphasize the need for health monitoring and early diagnosis in the risk group, and emphasize the importance of preventive measures.
Genetic predisposition to this disease
Genetic predisposition to primitive neuroectodermal tumor is studied in the context of the influence of various mutations on the development of the disease. Studies have shown that one of the most common mutations is associated with the TP53 gene, which plays a key role in cell defense mechanisms. Mutations in this gene can lead to disruption of the regulation of the cell cycle and apoptosis, which leads to an increased risk of malignant transformation of cells. In addition, changes in genes associated with cell signaling, such as MYC and CDK4, have also been found. Genetic variations may predispose patients to the development of PNET, especially in the context of hereditary syndromes such as Li-Fraumeni syndrome. More than 20% cases of PNET are familial, which emphasizes the need to consider genetic factors in diagnosis and treatment planning.
Risk factors for the development of this disease
Risk factors for the development of primitive neuroectodermal tumor are divided into physical and chemical. Physical factors include:
- Exposure to ionizing radiation, such as in patients who have undergone radiotherapy to treat other diseases.
- Genetic predisposition, as already mentioned, is the presence of mutations in certain genes.
- The impact of endocrine disorders potentially associated with tumors in children.
Chemical risk factors may include:
- Contact with certain chemicals, such as formaldehyde and other carcinogens used in industry.
- Environmental factors such as pollution.
In addition, there are other possible factors such as educational disadvantages and social conditions that may influence children's overall health and their susceptibility to cancer.
Diagnosis of this disease
Diagnostics of primitive neuroectodermal tumor includes several stages and methods aimed at timely detection of pathology. The main symptoms of the disease may vary depending on the location of the tumor, but most often manifest as:
- Headaches of varying intensity;
- Neurological disorders (numbness, weakness, convulsions);
- Changes in behavior and cognitive function;
- Problems with vision or hearing;
- Vomiting, especially in the morning.
Laboratory tests may include routine blood tests to assess the body's overall health and detect possible signs of inflammation or anemia. Radiological examinations such as MRI and CT scans are key in visualizing the tumor and its size, as well as assessing the extent of the process. Additionally, PET scanning may be used to assess the metabolic activity of tumor cells.
Other diagnostic tests may include neuropsychological testing to assess brain function, as well as a biopsy to confirm the diagnosis. Differential diagnosis is important to rule out other possible tumors, such as medulloblastomas and astrocytomas, as well as systemic diseases that present with neurological symptoms.
Treatment
Treatment of primitive neuroectodermal tumor requires a comprehensive approach and depends on the stage of the disease, the patient's age and general health. The main treatment methods include:
- General treatment - involves using a multidisciplinary team of doctors, including oncologists, neurosurgeons, internists and pediatricians, to develop an individualized treatment plan.
- Pharmacological treatment is the use of chemotherapy with cytostatic drugs. The regimens used may include a combination of different agents, such as vincristine, cyclophosphamide and methotrexate.
- Surgical treatment - radical resection of the tumor may be appropriate if it is possible and provides a chance of complete removal of the tumor.
- Other treatments may include radiation therapy, especially in cases of residual tumor mass after surgery, and immunotherapy, which is being studied in clinical trials.
Combination treatment provides higher survival rates and reduces the likelihood of relapse, which highlights the importance of early detection and a multidisciplinary approach to therapy.
List of medications used to treat this disease
Drugs used to treat primitive neuroectodermal tumor include:
- Vincristine;
- Cyclophosphamide;
- Methotrexate;
- Dotecuoxel;
- Topotecan;
- Lomustine.
These drugs can be used both in monotherapy and in complex regimens, depending on the individual characteristics of the disease and the patient's condition.
Disease monitoring
Monitoring of patients with primitive neuroectodermal tumor includes regular check-ups and routine examinations to assess remissions and possible relapses. Control stages may include:
- Routine MRI to assess tumor status;
- Laboratory tests to monitor general health;
- Neurological examinations to assess CNS function.
The prognosis of PNET depends largely on the early diagnosis and the effectiveness of treatment. Complete remission is possible, but the risk of relapse is high, especially in the first five years after treatment. Complications may include late effects of therapy, such as developmental disorders, cognitive decline, and other neurological disorders.
Age-related features of the disease
Primitive neuroectodermal tumor has its own age-related features. In children under 3 years of age, the disease manifests itself more often and has a more aggressive course. At this age, the tumor can cause severe neurological symptoms and situations that require immediate intervention. In schoolchildren and adolescents, the disease is less common, but can also be associated with high risks of metastasis. In adults, cases of PNET are significantly fewer, and they usually have later stages when they seek medical attention. The age factor also affects the tolerability of treatment and the complications that arise.
Questions and Answers
- What is primitive neuroectodermal tumor? Primitive neuroectodermal tumor is a malignant tumor arising from immature neurons, most commonly found in children.
- What are the main symptoms of PNET? The main symptoms include headaches, neurological disorders, behavioral changes and vomiting.
- How is PNET diagnosed? MRI, CT, laboratory tests and neurological evaluations are used for diagnosis.
- How is PNET treated? Treatment includes surgery, chemotherapy and radiotherapy depending on the stage of the disease.
- What is the prognosis for patients with PNET? The prognosis depends on the early diagnosis and the success of treatment, with a risk of relapse in the first five years after therapy.
